These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 37446056)
21. Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression. Wang SS; Liu Y; Zhang XT; Yu DQ Tohoku J Exp Med; 2023 May; 260(1):63-73. PubMed ID: 36823182 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834 [TBL] [Abstract][Full Text] [Related]
23. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857 [TBL] [Abstract][Full Text] [Related]
24. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Hack SP; Zhu AX; Wang Y Front Immunol; 2020; 11():598877. PubMed ID: 33250900 [TBL] [Abstract][Full Text] [Related]
25. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition. Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421 [TBL] [Abstract][Full Text] [Related]
26. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Xie S; Huang J; Qiao Q; Zang W; Hong S; Tan H; Dong C; Yang Z; Ni L Cancer Immunol Immunother; 2018 Nov; 67(11):1685-1694. PubMed ID: 30128738 [TBL] [Abstract][Full Text] [Related]
27. Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer. Wang T; Wu L; Wang S; Shi X; Liu H; Deng W Chin J Nat Med; 2023 May; 21(5):333-345. PubMed ID: 37245872 [TBL] [Abstract][Full Text] [Related]
28. Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. Salewski I; Henne J; Engster L; Schneider B; Lemcke H; Skorska A; Berlin P; Henze L; Junghanss C; Maletzki C Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206051 [TBL] [Abstract][Full Text] [Related]
29. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304 [TBL] [Abstract][Full Text] [Related]
30. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer. Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567 [TBL] [Abstract][Full Text] [Related]
31. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related]
32. Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model. Lee EJ; Yang JH; Yang HJ; Cho CK; Choi JG; Chung HS Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768213 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828 [TBL] [Abstract][Full Text] [Related]
34. Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. Hsu A; Huntington KE; De Souza A; Zhou L; Olszewski AJ; Makwana NP; Treaba DO; Cavalcante L; Giles FJ; Safran H; El-Deiry WS; Carneiro BA Cancer Biol Ther; 2022 Dec; 23(1):417-423. PubMed ID: 35815408 [TBL] [Abstract][Full Text] [Related]
35. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer. Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487 [TBL] [Abstract][Full Text] [Related]
36. Oxymatrine reduces expression of programmed death-ligand 1 by promoting DNA demethylation in colorectal cancer cells. Hua S; Gu M; Wang Y; Ban D; Ji H Clin Transl Oncol; 2021 Apr; 23(4):750-756. PubMed ID: 32737836 [TBL] [Abstract][Full Text] [Related]